Mode
Text Size
Log in / Sign up
N/A Completed N=1,410 Randomized Triple-blind Supportive Care

Pragmatic Trial of Messaging to Providers About Treatment of Heart Failure

Source: ClinicalTrials.gov NCT04514458 ↗
Enrolled (actual)
1,410
Serious AEs
0.0%
Results posted
Jul 2025
Primary outcomePrimary: Percentage of Patients With Heart Failure With Reduced Ejection Fraction (HFrEF) With an Increase in Prescribed HFrEF Therapy — 176; 117 Participants

Summary

A randomized controlled trial to compare the efficacy of an electronic health record-based alert informing providers about evidence-based medications for HFrEF versus usual care (no alert) in outpatient clinics across a single health system.

Outcome Measures

OutcomeResultp-value
PRIMARY
Percentage of Patients With Heart Failure With Reduced Ejection Fraction (HFrEF) With an Increase in Prescribed HFrEF Therapy
176; 117
SECONDARY
Percentage of Patients on Beta Blockers
606; 521
SECONDARY
Percentage of Patients on ACE Inhibitors
83; 92
SECONDARY
Percentage of Patients on ARBs
111; 85
SECONDARY
Percentage of Patients on ARNIs
334; 285
SECONDARY
Percentage of Patients on MRAs
232; 203
SECONDARY
Percentage of Patients on SGLT2 Inhibitors
144; 103
SECONDARY
Rate of One-year All-cause Mortality
75; 68
SECONDARY
Rate of 30-day Hospital Admission
47; 63
SECONDARY
Rate of 30-day All-cause Emergency Department Visits
86; 77
SECONDARY
Total Six-month Healthcare Costs
SECONDARY
Percentage of Filled Prescriptions
SECONDARY
Medication Dose of Any Prescribed Beta Blocker
SECONDARY
Medication Dose of Any Prescribed ACEi
SECONDARY
Medication Dose of Any Prescribed ARB
SECONDARY
Medication Dose of Any Prescribed ARNI
SECONDARY
Medication Dose of Any Prescribed MRA
SECONDARY
Medication Dose of Any Prescribed SGLT2 Inhibitor

Eligibility Criteria

Patient Inclusion Criteria:

  • Age 18 or over
  • Seen in eligible internal medicine or cardiology clinic
  • Left ventricular ejection fraction less than or equal to 40%
  • Registered in the Yale Heart Failure Registry

Patient Exclusion Criteria:

  • Opted out of EHR-based research
  • Under hospice care
  • Already receiving each targeted class of evidence-based HFrEF medical therapy

Selection of Providers:

  • Practicing at an eligible internal medicine or cardiology clinic
  • High frequency of visits by eligible patients based on retrospective chart review
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04514458). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search